THE MOLECULAR PATHOGENESIS OF NOONAN SYNDROME-ASSOCIATED ... · 1.2 Noonan syndrome and the RASopathies 13 1.2.1 Noonan syndrome 13 1.2.2 RASopathies: disorders clinically related
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
THE MOLECULAR PATHOGENESIS OF NOONAN
SYNDROME-ASSOCIATED RAF1 MUTATIONS
by
Xue Wu
A thesis submitted in conformity with the requirements
4. Krens, S.F., Spaink, H.P., and Snaar-Jagalska, B.E. 2006. Functions of the MAPK family in vertebrate-development. FEBS Lett 580:4984-4990.
5. Kyriakis, J.M., and Avruch, J. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81:807-869.
6. Kant, S., Schumacher, S., Singh, M.K., Kispert, A., Kotlyarov, A., and Gaestel, M. 2006. Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5. J Biol Chem 281:35511-35519.
7. Kasler, H.G., Victoria, J., Duramad, O., and Winoto, A. 2000. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol Cell Biol 20:8382-8389.
8. Kuo, W.L., Duke, C.J., Abe, M.K., Kaplan, E.L., Gomes, S., and Rosner, M.R. 2004. ERK7 expression and kinase activity is regulated by the ubiquitin-proteosome pathway. J Biol Chem 279:23073-23081.
9. Abe, M.K., Saelzler, M.P., Espinosa, R., 3rd, Kahle, K.T., Hershenson, M.B., Le Beau, M.M., and Rosner, M.R. 2002. ERK8, a new member of the mitogen-activated protein kinase family. J Biol Chem 277:16733-16743.
10. Abe, M.K., Kuo, W.L., Hershenson, M.B., and Rosner, M.R. 1999. Extracellular signal-regulated kinase 7 (ERK7), a novel ERK with a C-terminal domain that regulates its activity, its cellular localization, and cell growth. Mol Cell Biol 19:1301-1312.
11. Abe, M.K., Kahle, K.T., Saelzler, M.P., Orth, K., Dixon, J.E., and Rosner, M.R. 2001. ERK7 is an autoactivated member of the MAPK family. J Biol Chem 276:21272-21279.
12. Cobb, M.H., and Goldsmith, E.J. 1995. How MAP kinases are regulated. J Biol Chem 270:14843-14846.
13. Roux, P.P., and Blenis, J. 2004. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68:320-344.
171
14. Kyriakis, J.M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E.A., Ahmad, M.F., Avruch, J., and Woodgett, J.R. 1994. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369:156-160.
15. Das, S., Cho, J., Lambertz, I., Kelliher, M.A., Eliopoulos, A.G., Du, K., and Tsichlis, P.N. 2005. Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem 280:23748-23757.
16. Yujiri, T., Sather, S., Fanger, G.R., and Johnson, G.L. 1998. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. Science 282:1911-1914.
17. Dupre, A., Haccard, O., and Jessus, C. 2011. Mos in the oocyte: how to use MAPK independently of growth factors and transcription to control meiotic divisions. J Signal Transduct 2011:350412.
18. Drew, B.A., Burow, M.E., and Beckman, B.S. 2012. MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta 1825:37-48.
19. Weston, C.R., and Davis, R.J. 2002. The JNK signal transduction pathway. Curr Opin Genet Dev 12:14-21.
20. Ip, Y.T., and Davis, R.J. 1998. Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. Curr Opin Cell Biol 10:205-219.
21. Raingeaud, J., Gupta, S., Rogers, J.S., Dickens, M., Han, J., Ulevitch, R.J., and Davis, R.J. 1995. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270:7420-7426.
22. Zarubin, T., and Han, J. 2005. Activation and signaling of the p38 MAP kinase pathway. Cell Res 15:11-18.
23. Derijard, B., Raingeaud, J., Barrett, T., Wu, I.H., Han, J., Ulevitch, R.J., and Davis, R.J. 1995. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267:682-685.
24. Roskoski, R., Jr. 2012. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 66:105-143.
25. Rogge, R.D., Karlovich, C.A., and Banerjee, U. 1991. Genetic dissection of a neurodevelopmental pathway: Son of sevenless functions downstream of the sevenless and EGF receptor tyrosine kinases. Cell 64:39-48.
26. Malumbres, M., and Barbacid, M. 2003. RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459-465.
27. Giehl, K. 2005. Oncogenic Ras in tumour progression and metastasis. Biol Chem 386:193-205.
172
28. McCubrey, J.A., Steelman, L.S., Chappell, W.H., Abrams, S.L., Wong, E.W., Chang, F., Lehmann, B., Terrian, D.M., Milella, M., Tafuri, A., et al. 2007. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-1284.
29. Downward, J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22.
30. Kohno, M., and Pouyssegur, J. 2006. Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200-211.
31. Bentires-Alj, M., Kontaridis, M.I., and Neel, B.G. 2006. Stops along the RAS pathway in human genetic disease. Nat Med 12:283-285.
32. Tidyman, W.E., and Rauen, K.A. 2009. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 19:230-236.
33. Vakiani, E., and Solit, D.B. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 223:219-229.
34. Bos, J.L. 1989. ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689.
35. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
36. Garnett, M.J., and Marais, R. 2004. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313-319.
37. Lemmon, M.A., and Schlessinger, J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134.
39. Mol, C.D., Dougan, D.R., Schneider, T.R., Skene, R.J., Kraus, M.L., Scheibe, D.N., Snell, G.P., Zou, H., Sang, B.C., and Wilson, K.P. 2004. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279:31655-31663.
40. Niu, X.L., Peters, K.G., and Kontos, C.D. 2002. Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism. J Biol Chem 277:31768-31773.
41. Knowles, P.P., Murray-Rust, J., Kjaer, S., Scott, R.P., Hanrahan, S., Santoro, M., Ibanez, C.F., and McDonald, N.Q. 2006. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281:33577-33587.
173
42. Zhang, X., Gureasko, J., Shen, K., Cole, P.A., and Kuriyan, J. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149.
43. Pawson, T., Gish, G.D., and Nash, P. 2001. SH2 domains, interaction modules and cellular wiring. Trends Cell Biol 11:504-511.
44. Margolis, B., Borg, J.P., Straight, S., and Meyer, D. 1999. The function of PTB domain proteins. Kidney Int 56:1230-1237.
45. Li, N., Batzer, A., Daly, R., Yajnik, V., Skolnik, E., Chardin, P., Bar-Sagi, D., Margolis, B., and Schlessinger, J. 1993. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 363:85-88.
46. Rojas, M., Yao, S., and Lin, Y.Z. 1996. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 271:27456-27461.
47. Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., Grignani, F., Pawson, T., and Pelicci, P.G. 1992. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70:93-104.
48. Suenaga, A., Hatakeyama, M., Kiyatkin, A.B., Radhakrishnan, R., Taiji, M., and Kholodenko, B.N. 2009. Molecular dynamics simulations reveal that Tyr-317 phosphorylation reduces Shc binding affinity for phosphotyrosyl residues of epidermal growth factor receptor. Biophys J 96:2278-2288.
49. Dance, M., Montagner, A., Salles, J.P., Yart, A., and Raynal, P. 2008. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal 20:453-459.
50. Vogel, W., and Ullrich, A. 1996. Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584. Cell Growth Differ 7:1589-1597.
51. Li, W., Nishimura, R., Kashishian, A., Batzer, A.G., Kim, W.J., Cooper, J.A., and Schlessinger, J. 1994. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell Biol 14:509-517.
52. Bennett, A.M., Tang, T.L., Sugimoto, S., Walsh, C.T., and Neel, B.G. 1994. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci U S A 91:7335-7339.
53. Araki, T., Nawa, H., and Neel, B.G. 2003. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem 278:41677-41684.
54. Tefft, D., Lee, M., Smith, S., Crowe, D.L., Bellusci, S., and Warburton, D. 2002. mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins. Am J Physiol Lung Cell Mol Physiol 283:L700-706.
174
55. Hanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K., and Nishida, E. 2004. Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. J Biol Chem 279:22992-22995.
56. Tefft, D., De Langhe, S.P., Del Moral, P.M., Sala, F., Shi, W., Bellusci, S., and Warburton, D. 2005. A novel function for the protein tyrosine phosphatase Shp2 during lung branching morphogenesis. Dev Biol 282:422-431.
57. Agazie, Y.M., and Hayman, M.J. 2003. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 23:7875-7886.
58. Montagner, A., Yart, A., Dance, M., Perret, B., Salles, J.P., and Raynal, P. 2005. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J Biol Chem 280:5350-5360.
59. Ren, Y., Meng, S., Mei, L., Zhao, Z.J., Jove, R., and Wu, J. 2004. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem 279:8497-8505.
60. Zhang, S.Q., Yang, W., Kontaridis, M.I., Bivona, T.G., Wen, G., Araki, T., Luo, J., Thompson, J.A., Schraven, B.L., Philips, M.R., et al. 2004. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell 13:341-355.
61. Yang, W., Klaman, L.D., Chen, B., Araki, T., Harada, H., Thomas, S.M., George, E.L., and Neel, B.G. 2006. An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev Cell 10:317-327.
62. Della Rocca, G.J., van Biesen, T., Daaka, Y., Luttrell, D.K., Luttrell, L.M., and Lefkowitz, R.J. 1997. Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors. Convergence of Gi- and Gq-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase. J Biol Chem 272:19125-19132.
63. Goldsmith, Z.G., and Dhanasekaran, D.N. 2007. G protein regulation of MAPK networks. Oncogene 26:3122-3142.
64. Kumar, C.C. 1998. Signaling by integrin receptors. Oncogene 17:1365-1373.
65. Shimizu, K., Goldfarb, M., Suard, Y., Perucho, M., Li, Y., Kamata, T., Feramisco, J., Stavnezer, E., Fogh, J., and Wigler, M.H. 1983. Three human transforming genes are related to the viral ras oncogenes. Proc Natl Acad Sci U S A 80:2112-2116.
66. Gorfe, A.A. 2010. Mechanisms of allostery and membrane attachment in Ras GTPases: implications for anti-cancer drug discovery. Curr Med Chem 17:1-9.
67. Rocks, O., Peyker, A., Kahms, M., Verveer, P.J., Koerner, C., Lumbierres, M., Kuhlmann, J., Waldmann, H., Wittinghofer, A., and Bastiaens, P.I. 2005. An acylation
175
cycle regulates localization and activity of palmitoylated Ras isoforms. Science 307:1746-1752.
68. Avruch, J., Zhang, X.F., and Kyriakis, J.M. 1994. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 19:279-283.
69. Vigil, D., Cherfils, J., Rossman, K.L., and Der, C.J. 2010. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 10:842-857.
70. Alessi, D.R., Saito, Y., Campbell, D.G., Cohen, P., Sithanandam, G., Rapp, U., Ashworth, A., Marshall, C.J., and Cowley, S. 1994. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. Embo J 13:1610-1619.
71. Pritchard, C.A., Samuels, M.L., Bosch, E., and McMahon, M. 1995. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol 15:6430-6442.
72. Papin, C., Denouel, A., Calothy, G., and Eychene, A. 1996. Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. Oncogene 12:2213-2221.
73. Marais, R., Light, Y., Paterson, H.F., Mason, C.S., and Marshall, C.J. 1997. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272:4378-4383.
74. Papin, C., Denouel-Galy, A., Laugier, D., Calothy, G., and Eychene, A. 1998. Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf. J Biol Chem 273:24939-24947.
75. Roskoski, R., Jr. 2012. MEK1/2 dual-specificity protein kinases: structure and regulation. Biochem Biophys Res Commun 417:5-10.
76. Park, E.R., Eblen, S.T., and Catling, A.D. 2007. MEK1 activation by PAK: a novel mechanism. Cell Signal 19:1488-1496.
77. Eblen, S.T., Slack-Davis, J.K., Tarcsafalvi, A., Parsons, J.T., Weber, M.J., and Catling, A.D. 2004. Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol Cell Biol 24:2308-2317.
78. Gopalbhai, K., Jansen, G., Beauregard, G., Whiteway, M., Dumas, F., Wu, C., and Meloche, S. 2003. Negative regulation of MAPKK by phosphorylation of a conserved serine residue equivalent to Ser212 of MEK1. J Biol Chem 278:8118-8125.
79. Catalanotti, F., Reyes, G., Jesenberger, V., Galabova-Kovacs, G., de Matos Simoes, R., Carugo, O., and Baccarini, M. 2009. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol 16:294-303.
80. Lloyd, A.C. 2006. Distinct functions for ERKs? J Biol 5:13.
176
81. Boulton, T.G., Yancopoulos, G.D., Gregory, J.S., Slaughter, C., Moomaw, C., Hsu, J., and Cobb, M.H. 1990. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 249:64-67.
82. Boulton, T.G., Nye, S.H., Robbins, D.J., Ip, N.Y., Radziejewska, E., Morgenbesser, S.D., DePinho, R.A., Panayotatos, N., Cobb, M.H., and Yancopoulos, G.D. 1991. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65:663-675.
83. Lefloch, R., Pouyssegur, J., and Lenormand, P. 2008. Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol 28:511-527.
84. Lefloch, R., Pouyssegur, J., and Lenormand, P. 2009. Total ERK1/2 activity regulates cell proliferation. Cell Cycle 8:705-711.
85. Pages, G., Guerin, S., Grall, D., Bonino, F., Smith, A., Anjuere, F., Auberger, P., and Pouyssegur, J. 1999. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286:1374-1377.
86. Yao, Y., Li, W., Wu, J., Germann, U.A., Su, M.S., Kuida, K., and Boucher, D.M. 2003. Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. Proc Natl Acad Sci U S A 100:12759-12764.
87. Hatano, N., Mori, Y., Oh-hora, M., Kosugi, A., Fujikawa, T., Nakai, N., Niwa, H., Miyazaki, J., Hamaoka, T., and Ogata, M. 2003. Essential role for ERK2 mitogen-activated protein kinase in placental development. Genes Cells 8:847-856.
88. Saba-El-Leil, M.K., Vella, F.D., Vernay, B., Voisin, L., Chen, L., Labrecque, N., Ang, S.L., and Meloche, S. 2003. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep 4:964-968.
89. Bost, F., Aouadi, M., Caron, L., Even, P., Belmonte, N., Prot, M., Dani, C., Hofman, P., Pages, G., Pouyssegur, J., et al. 2005. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 54:402-411.
90. Ferrell, J.E., Jr., and Bhatt, R.R. 1997. Mechanistic studies of the dual phosphorylation of mitogen-activated protein kinase. J Biol Chem 272:19008-19016.
91. Tanoue, T., Adachi, M., Moriguchi, T., and Nishida, E. 2000. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2:110-116.
92. Yoon, S., and Seger, R. 2006. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24:21-44.
93. Northwood, I.C., Gonzalez, F.A., Wartmann, M., Raden, D.L., and Davis, R.J. 1991. Isolation and characterization of two growth factor-stimulated protein kinases that
177
phosphorylate the epidermal growth factor receptor at threonine 669. J Biol Chem 266:15266-15276.
94. Li, X., Huang, Y., Jiang, J., and Frank, S.J. 2008. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell Signal 20:2145-2155.
95. Dong, C., Waters, S.B., Holt, K.H., and Pessin, J.E. 1996. SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J Biol Chem 271:6328-6332.
96. Kamioka, Y., Yasuda, S., Fujita, Y., Aoki, K., and Matsuda, M. 2010. Multiple decisive phosphorylation sites for the negative feedback regulation of SOS1 via ERK. J Biol Chem 285:33540-33548.
97. Dougherty, M.K., Muller, J., Ritt, D.A., Zhou, M., Zhou, X.Z., Copeland, T.D., Conrads, T.P., Veenstra, T.D., Lu, K.P., and Morrison, D.K. 2005. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17:215-224.
98. Ritt, D.A., Monson, D.M., Specht, S.I., and Morrison, D.K. 2010. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol 30:806-819.
99. Brondello, J.M., Pouyssegur, J., and McKenzie, F.R. 1999. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286:2514-2517.
100. Peng, D.J., Zhou, J.Y., and Wu, G.S. 2010. Post-translational regulation of mitogen-activated protein kinase phosphatase-2 (MKP-2) by ERK. Cell Cycle 9:4650-4655.
101. Waskiewicz, A.J., Flynn, A., Proud, C.G., and Cooper, J.A. 1997. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. Embo J 16:1909-1920.
102. Wendel, H.G., Silva, R.L., Malina, A., Mills, J.R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., et al. 2007. Dissecting eIF4E action in tumorigenesis. Genes Dev 21:3232-3237.
103. Chen, R.H., Chung, J., and Blenis, J. 1991. Regulation of pp90rsk phosphorylation and S6 phosphotransferase activity in Swiss 3T3 cells by growth factor-, phorbol ester-, and cyclic AMP-mediated signal transduction. Mol Cell Biol 11:1861-1867.
104. Anjum, R., and Blenis, J. 2008. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9:747-758.
105. Gavin, A.C., and Nebreda, A.R. 1999. A MAP kinase docking site is required for phosphorylation and activation of p90(rsk)/MAPKAP kinase-1. Curr Biol 9:281-284.
178
106. Carriere, A., Ray, H., Blenis, J., and Roux, P.P. 2008. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 13:4258-4275.
107. Roux, P.P., Shahbazian, D., Vu, H., Holz, M.K., Cohen, M.S., Taunton, J., Sonenberg, N., and Blenis, J. 2007. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282:14056-14064.
108. Roux, P.P., Ballif, B.A., Anjum, R., Gygi, S.P., and Blenis, J. 2004. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 101:13489-13494.
109. Carriere, A., Cargnello, M., Julien, L.A., Gao, H., Bonneil, E., Thibault, P., and Roux, P.P. 2008. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 18:1269-1277.
110. Shahbazian, D., Roux, P.P., Mieulet, V., Cohen, M.S., Raught, B., Taunton, J., Hershey, J.W., Blenis, J., Pende, M., and Sonenberg, N. 2006. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. Embo J 25:2781-2791.
111. Fujita, N., Sato, S., and Tsuruo, T. 2003. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 278:49254-49260.
112. Frodin, M., and Gammeltoft, S. 1999. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 151:65-77.
113. Brunet, A., Roux, D., Lenormand, P., Dowd, S., Keyse, S., and Pouyssegur, J. 1999. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. Embo J 18:664-674.
114. Deak, M., Clifton, A.D., Lucocq, L.M., and Alessi, D.R. 1998. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. Embo J 17:4426-4441.
115. Gupta, P., and Prywes, R. 2002. ATF1 phosphorylation by the ERK MAPK pathway is required for epidermal growth factor-induced c-jun expression. J Biol Chem 277:50550-50556.
116. Wiggin, G.R., Soloaga, A., Foster, J.M., Murray-Tait, V., Cohen, P., and Arthur, J.S. 2002. MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22:2871-2881.
117. Soloaga, A., Thomson, S., Wiggin, G.R., Rampersaud, N., Dyson, M.H., Hazzalin, C.A., Mahadevan, L.C., and Arthur, J.S. 2003. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. Embo J 22:2788-2797.
179
118. Marais, R., Wynne, J., and Treisman, R. 1993. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73:381-393.
119. Price, M.A., Rogers, A.E., and Treisman, R. 1995. Comparative analysis of the ternary complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET). Embo J 14:2589-2601.
120. Gille, H., Kortenjann, M., Thomae, O., Moomaw, C., Slaughter, C., Cobb, M.H., and Shaw, P.E. 1995. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. Embo J 14:951-962.
121. Pelengaris, S., Khan, M., and Evan, G. 2002. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2:764-776.
122. Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., and Nevins, J.R. 2000. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14:2501-2514.
123. Monje, P., Hernandez-Losa, J., Lyons, R.J., Castellone, M.D., and Gutkind, J.S. 2005. Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem 280:35081-35084.
124. Felton-Edkins, Z.A., Fairley, J.A., Graham, E.L., Johnston, I.M., White, R.J., and Scott, P.H. 2003. The mitogen-activated protein (MAP) kinase ERK induces tRNA synthesis by phosphorylating TFIIIB. Embo J 22:2422-2432.
125. Stefanovsky, V.Y., Pelletier, G., Hannan, R., Gagnon-Kugler, T., Rothblum, L.I., and Moss, T. 2001. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell 8:1063-1073.
126. Noonan, J.A. 1968. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 116:373-380.
127. Nora, J.J., Nora, A.H., Sinha, A.K., Spangler, R.D., and Lubs, H.A. 1974. The Ullrich-Noonan syndrome (Turner phenotype). Am J Dis Child 127:48-55.
128. Noonan, J.A. 1994. Noonan syndrome. An update and review for the primary pediatrician. Clin Pediatr (Phila) 33:548-555.
129. Allanson, J.E. 2007. Noonan syndrome. Am J Med Genet C Semin Med Genet 145C:274-279.
130. van der Burgt, I. 2007. Noonan syndrome. Orphanet J Rare Dis 2:4.
131. Romano, A.A., Blethen, S.L., Dana, K., and Noto, R.A. 1996. Growth hormone treatment in Noonan syndrome: the National Cooperative Growth Study experience. J Pediatr 128:S18-21.
180
132. Noordam, C., Van der Burgt, I., Sengers, R.C., Delemarre-van de Waal, H.A., and Otten, B.J. 2001. Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial. Acta Paediatr 90:889-894.
133. Binder, G., Neuer, K., Ranke, M.B., and Wittekindt, N.E. 2005. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 90:5377-5381.
134. De Rocca Serra-Nedelec, A., Edouard, T., Treguer, K., Tajan, M., Araki, T., Dance, M., Mus, M., Montagner, A., Tauber, M., Salles, J.P., et al. 2012. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature. Proc Natl Acad Sci U S A 109:4257-4262.
135. Burch, M., Sharland, M., Shinebourne, E., Smith, G., Patton, M., and McKenna, W. 1993. Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol 22:1189-1192.
136. Marino, B., Digilio, M.C., Toscano, A., Giannotti, A., and Dallapiccola, B. 1999. Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 135:703-706.
137. Shah, N., Rodriguez, M., Louis, D.S., Lindley, K., and Milla, P.J. 1999. Feeding difficulties and foregut dysmotility in Noonan's syndrome. Arch Dis Child 81:28-31.
138. Cesarini, L., Alfieri, P., Pantaleoni, F., Vasta, I., Cerutti, M., Petrangeli, V., Mariotti, P., Leoni, C., Ricci, D., Vicari, S., et al. 2009. Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade. Am J Med Genet A 149A:140-146.
139. Pierpont, E.I., Pierpont, M.E., Mendelsohn, N.J., Roberts, A.E., Tworog-Dube, E., and Seidenberg, M.S. 2009. Genotype differences in cognitive functioning in Noonan syndrome. Genes Brain Behav 8:275-282.
140. Bastida, P., Garcia-Minaur, S., Ezquieta, B., Dapena, J.L., and Sanchez de Toledo, J. 2011. Myeloproliferative disorder in Noonan syndrome. J Pediatr Hematol Oncol 33:e43-45.
141. Niemeyer, C.M., and Kratz, C.P. 2008. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 140:610-624.
142. Kratz, C.P., Niemeyer, C.M., Castleberry, R.P., Cetin, M., Bergstrasser, E., Emanuel, P.D., Hasle, H., Kardos, G., Klein, C., Kojima, S., et al. 2005. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106:2183-2185.
143. Allanson, J.E., Hall, J.G., Hughes, H.E., Preus, M., and Witt, R.D. 1985. Noonan syndrome: the changing phenotype. Am J Med Genet 21:507-514.
181
144. Aoki, Y., Niihori, T., Narumi, Y., Kure, S., and Matsubara, Y. 2008. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 29:992-1006.
145. Tartaglia, M., Mehler, E.L., Goldberg, R., Zampino, G., Brunner, H.G., Kremer, H., van der Burgt, I., Crosby, A.H., Ion, A., Jeffery, S., et al. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465-468.
147. Tartaglia, M., Pennacchio, L.A., Zhao, C., Yadav, K.K., Fodale, V., Sarkozy, A., Pandit, B., Oishi, K., Martinelli, S., Schackwitz, W., et al. 2007. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39:75-79.
148. Razzaque, M.A., Nishizawa, T., Komoike, Y., Yagi, H., Furutani, M., Amo, R., Kamisago, M., Momma, K., Katayama, H., Nakagawa, M., et al. 2007. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39:1013-1017.
149. Pandit, B., Sarkozy, A., Pennacchio, L.A., Carta, C., Oishi, K., Martinelli, S., Pogna, E.A., Schackwitz, W., Ustaszewska, A., Landstrom, A., et al. 2007. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39:1007-1012.
150. Schubbert, S., Zenker, M., Rowe, S.L., Boll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.E., et al. 2006. Germline KRAS mutations cause Noonan syndrome. Nat Genet 38:331-336.
151. Zenker, M., Lehmann, K., Schulz, A.L., Barth, H., Hansmann, D., Koenig, R., Korinthenberg, R., Kreiss-Nachtsheim, M., Meinecke, P., Morlot, S., et al. 2007. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 44:131-135.
152. Cirstea, I.C., Kutsche, K., Dvorsky, R., Gremer, L., Carta, C., Horn, D., Roberts, A.E., Lepri, F., Merbitz-Zahradnik, T., Konig, R., et al. 2010. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet 42:27-29.
153. Sarkozy, A., Carta, C., Moretti, S., Zampino, G., Digilio, M.C., Pantaleoni, F., Scioletti, A.P., Esposito, G., Cordeddu, V., Lepri, F., et al. 2009. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat 30:695-702.
154. Neel, B.G., Gu, H., and Pao, L. 2003. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28:284-293.
155. Mohi, M.G., and Neel, B.G. 2007. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17:23-30.
182
156. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M.J., and Shoelson, S.E. 1998. Crystal structure of the tyrosine phosphatase SHP-2. Cell 92:441-450.
157. Keilhack, H., David, F.S., McGregor, M., Cantley, L.C., and Neel, B.G. 2005. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 280:30984-30993.
158. Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., Burgt, I., Palleschi, A., Petrucci, T.C., et al. 2006. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78:279-290.
159. Martinelli, S., Torreri, P., Tinti, M., Stella, L., Bocchinfuso, G., Flex, E., Grottesi, A., Ceccarini, M., Palleschi, A., Cesareni, G., et al. 2008. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum Mol Genet 17:2018-2029.
160. Zenker, M., Horn, D., Wieczorek, D., Allanson, J., Pauli, S., van der Burgt, I., Doerr, H.G., Gaspar, H., Hofbeck, M., Gillessen-Kaesbach, G., et al. 2007. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet 44:651-656.
161. Kratz, C.P., Zampino, G., Kriek, M., Kant, S.G., Leoni, C., Pantaleoni, F., Oudesluys-Murphy, A.M., Di Rocco, C., Kloska, S.P., Tartaglia, M., et al. 2009. Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations. Am J Med Genet A 149A:1036-1040.
162. Schubbert, S., Bollag, G., Lyubynska, N., Nguyen, H., Kratz, C.P., Zenker, M., Niemeyer, C.M., Molven, A., and Shannon, K. 2007. Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 27:7765-7770.
163. Light, Y., Paterson, H., and Marais, R. 2002. 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol Cell Biol 22:4984-4996.
164. Kubicek, M., Pacher, M., Abraham, D., Podar, K., Eulitz, M., and Baccarini, M. 2002. Dephosphorylation of Ser-259 regulates Raf-1 membrane association. J Biol Chem 277:7913-7919.
165. Kobayashi, T., Aoki, Y., Niihori, T., Cave, H., Verloes, A., Okamoto, N., Kawame, H., Fujiwara, I., Takada, F., Ohata, T., et al. 2010. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat 31:284-294.
166. Molzan, M., Schumacher, B., Ottmann, C., Baljuls, A., Polzien, L., Weyand, M., Thiel, P., Rose, R., Rose, M., Kuhenne, P., et al. 2010. Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol Cell Biol 30:4698-4711.
183
167. Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M., Jones, C.M., Marshall, C.J., Springer, C.J., Barford, D., et al. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867.
168. Garnett, M.J., Rana, S., Paterson, H., Barford, D., and Marais, R. 2005. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20:963-969.
169. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., and Rosen, N. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-430.
170. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B.J., Anderson, D.J., Alvarado, R., Ludlam, M.J., Stokoe, D., Gloor, S.L., Vigers, G., et al. 2010. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-435.
171. Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cave, H., Verloes, A., Okamoto, N., Hennekam, R.C., Gillessen-Kaesbach, G., Wieczorek, D., et al. 2006. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38:294-296.
172. Rodriguez-Viciana, P., Tetsu, O., Tidyman, W.E., Estep, A.L., Conger, B.A., Cruz, M.S., McCormick, F., and Rauen, K.A. 2006. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311:1287-1290.
173. Tartaglia, M., Kalidas, K., Shaw, A., Song, X., Musat, D.L., van der Burgt, I., Brunner, H.G., Bertola, D.R., Crosby, A., Ion, A., et al. 2002. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70:1555-1563.
174. Zenker, M., Buheitel, G., Rauch, R., Koenig, R., Bosse, K., Kress, W., Tietze, H.U., Doerr, H.G., Hofbeck, M., Singer, H., et al. 2004. Genotype-phenotype correlations in Noonan syndrome. J Pediatr 144:368-374.
175. Tartaglia, M., Niemeyer, C.M., Fragale, A., Song, X., Buechner, J., Jung, A., Hahlen, K., Hasle, H., Licht, J.D., and Gelb, B.D. 2003. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34:148-150.
176. Digilio, M.C., Sarkozy, A., de Zorzi, A., Pacileo, G., Limongelli, G., Mingarelli, R., Calabro, R., Marino, B., and Dallapiccola, B. 2006. LEOPARD syndrome: clinical diagnosis in the first year of life. Am J Med Genet A 140:740-746.
177. Digilio, M.C., Conti, E., Sarkozy, A., Mingarelli, R., Dottorini, T., Marino, B., Pizzuti, A., and Dallapiccola, B. 2002. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71:389-394.
178. Legius, E., Schrander-Stumpel, C., Schollen, E., Pulles-Heintzberger, C., Gewillig, M., and Fryns, J.P. 2002. PTPN11 mutations in LEOPARD syndrome. J Med Genet 39:571-574.
184
179. Hanna, N., Montagner, A., Lee, W.H., Miteva, M., Vidal, M., Vidaud, M., Parfait, B., and Raynal, P. 2006. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett 580:2477-2482.
180. Kontaridis, M.I., Swanson, K.D., David, F.S., Barford, D., and Neel, B.G. 2006. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 281:6785-6792.
181. Koudova, M., Seemanova, E., and Zenker, M. 2009. Novel BRAF mutation in a patient with LEOPARD syndrome and normal intelligence. Eur J Med Genet 52:337-340.
182. Mazzanti, L., Cacciari, E., Cicognani, A., Bergamaschi, R., Scarano, E., and Forabosco, A. 2003. Noonan-like syndrome with loose anagen hair: a new syndrome? Am J Med Genet A 118A:279-286.
183. Cordeddu, V., Di Schiavi, E., Pennacchio, L.A., Ma'ayan, A., Sarkozy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W., et al. 2009. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet 41:1022-1026.
184. Capalbo, D., Melis, D., De Martino, L., Palamaro, L., Riccomagno, S., Bona, G., Cordeddu, V., Pignata, C., and Salerno, M. 2012. Noonan-like syndrome with loose anagen hair associated with growth hormone insensitivity and atypical neurological manifestations. Am J Med Genet A 158A:856-860.
185. Cantatore-Francis, J.L., and Orlow, S.J. 2009. Practical guidelines for evaluation of loose anagen hair syndrome. Arch Dermatol 145:1123-1128.
186. Matsunaga-Udagawa, R., Fujita, Y., Yoshiki, S., Terai, K., Kamioka, Y., Kiyokawa, E., Yugi, K., Aoki, K., and Matsuda, M. 2010. The scaffold protein Shoc2/SUR-8 accelerates the interaction of Ras and Raf. J Biol Chem 285:7818-7826.
187. Martinelli, S., De Luca, A., Stellacci, E., Rossi, C., Checquolo, S., Lepri, F., Caputo, V., Silvano, M., Buscherini, F., Consoli, F., et al. 2010. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 87:250-257.
188. Perez, B., Mechinaud, F., Galambrun, C., Ben Romdhane, N., Isidor, B., Philip, N., Derain-Court, J., Cassinat, B., Lachenaud, J., Kaltenbach, S., et al. 2010. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet 47:686-691.
189. Niemeyer, C.M., Kang, M.W., Shin, D.H., Furlan, I., Erlacher, M., Bunin, N.J., Bunda, S., Finklestein, J.Z., Sakamoto, K.M., Gorr, T.A., et al. 2010. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 42:794-800.
190. Friedman, J.M., and Birch, P.H. 1997. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 70:138-143.
193. Brems, H., Chmara, M., Sahbatou, M., Denayer, E., Taniguchi, K., Kato, R., Somers, R., Messiaen, L., De Schepper, S., Fryns, J.P., et al. 2007. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39:1120-1126.
194. Messiaen, L., Yao, S., Brems, H., Callens, T., Sathienkijkanchai, A., Denayer, E., Spencer, E., Arn, P., Babovic-Vuksanovic, D., Bay, C., et al. 2009. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. Jama 302:2111-2118.
195. Pasmant, E., Sabbagh, A., Hanna, N., Masliah-Planchon, J., Jolly, E., Goussard, P., Ballerini, P., Cartault, F., Barbarot, S., Landman-Parker, J., et al. 2009. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet 46:425-430.
196. Wakioka, T., Sasaki, A., Kato, R., Shouda, T., Matsumoto, A., Miyoshi, K., Tsuneoka, M., Komiya, S., Baron, R., and Yoshimura, A. 2001. Spred is a Sprouty-related suppressor of Ras signalling. Nature 412:647-651.
197. Reynolds, J.F., Neri, G., Herrmann, J.P., Blumberg, B., Coldwell, J.G., Miles, P.V., and Opitz, J.M. 1986. New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement--the CFC syndrome. Am J Med Genet 25:413-427.
198. Roberts, A., Allanson, J., Jadico, S.K., Kavamura, M.I., Noonan, J., Opitz, J.M., Young, T., and Neri, G. 2006. The cardiofaciocutaneous syndrome. J Med Genet 43:833-842.
199. Costello, J.M. 1977. A new syndrome: mental subnormality and nasal papillomata. Aust Paediatr J 13:114-118.
200. Hennekam, R.C. 2003. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 117C:42-48.
201. Gripp, K.W. 2005. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137C:72-77.
202. Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, M., Kato, K., Suzuki, Y., Kure, S., et al. 2005. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37:1038-1040.
203. Pylayeva-Gupta, Y., Grabocka, E., and Bar-Sagi, D. 2011. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11:761-774.
204. Araki, T., Mohi, M.G., Ismat, F.A., Bronson, R.T., Williams, I.R., Kutok, J.L., Yang, W., Pao, L.I., Gilliland, D.G., Epstein, J.A., et al. 2004. Mouse model of Noonan syndrome
186
reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10:849-857.
205. Brannan, C.I., Perkins, A.S., Vogel, K.S., Ratner, N., Nordlund, M.L., Reid, S.W., Buchberg, A.M., Jenkins, N.A., Parada, L.F., and Copeland, N.G. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 8:1019-1029.
206. Lakkis, M.M., and Epstein, J.A. 1998. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125:4359-4367.
207. Krenz, M., Gulick, J., Osinska, H.E., Colbert, M.C., Molkentin, J.D., and Robbins, J. 2008. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome. Proc Natl Acad Sci U S A 105:18930-18935.
208. Nakamura, T., Colbert, M., Krenz, M., Molkentin, J.D., Hahn, H.S., Dorn, G.W., 2nd, and Robbins, J. 2007. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest 117:2123-2132.
209. Nakamura, T., Gulick, J., Pratt, R., and Robbins, J. 2009. Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations. Proc Natl Acad Sci U S A 106:15436-15441.
210. Araki, T., Chan, G., Newbigging, S., Morikawa, L., Bronson, R.T., and Neel, B.G. 2009. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A 106:4736-4741.
211. Chen, P.C., Wakimoto, H., Conner, D., Araki, T., Yuan, T., Roberts, A., Seidman, C.E., Bronson, R., Neel, B.G., Seidman, J.G., et al. 2010 Nov1. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J Clin Invest Epub ahead of print.
212. Rapp, U.R., Goldsborough, M.D., Mark, G.E., Bonner, T.I., Groffen, J., Reynolds, F.H., Jr., and Stephenson, J.R. 1983. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U S A 80:4218-4222.
213. Sutrave, P., Bonner, T.I., Rapp, U.R., Jansen, H.W., Patschinsky, T., and Bister, K. 1984. Nucleotide sequence of avian retroviral oncogene v-mil: homologue of murine retroviral oncogene v-raf. Nature 309:85-88.
214. Moelling, K., Heimann, B., Beimling, P., Rapp, U.R., and Sander, T. 1984. Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature 312:558-561.
215. Bonner, T.I., Kerby, S.B., Sutrave, P., Gunnell, M.A., Mark, G., and Rapp, U.R. 1985. Structure and biological activity of human homologs of the raf/mil oncogene. Mol Cell Biol 5:1400-1407.
187
216. Jansen, H.W., and Bister, K. 1985. Nucleotide sequence analysis of the chicken gene c-mil, the progenitor of the retroviral oncogene v-mil. Virology 143:359-367.
217. Wasylyk, C., Wasylyk, B., Heidecker, G., Huleihel, M., and Rapp, U.R. 1989. Expression of raf oncogenes activates the PEA1 transcription factor motif. Mol Cell Biol 9:2247-2250.
218. Kolch, W., Heidecker, G., Lloyd, P., and Rapp, U.R. 1991. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349:426-428.
219. Jamal, S., and Ziff, E. 1990. Transactivation of c-fos and beta-actin genes by raf as a step in early response to transmembrane signals. Nature 344:463-466.
221. Dent, P., Haser, W., Haystead, T.A., Vincent, L.A., Roberts, T.M., and Sturgill, T.W. 1992. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 257:1404-1407.
222. Zhang, X.F., Settleman, J., Kyriakis, J.M., Takeuchi-Suzuki, E., Elledge, S.J., Marshall, M.S., Bruder, J.T., Rapp, U.R., and Avruch, J. 1993. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364:308-313.
223. Warne, P.H., Viciana, P.R., and Downward, J. 1993. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364:352-355.
224. Vojtek, A.B., Hollenberg, S.M., and Cooper, J.A. 1993. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74:205-214.
225. Van Aelst, L., Barr, M., Marcus, S., Polverino, A., and Wigler, M. 1993. Complex formation between RAS and RAF and other protein kinases. Proc Natl Acad Sci U S A 90:6213-6217.
226. Moodie, S.A., Willumsen, B.M., Weber, M.J., and Wolfman, A. 1993. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260:1658-1661.
227. Chen, J., Fujii, K., Zhang, L., Roberts, T., and Fu, H. 2001. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci U S A 98:7783-7788.
228. O'Neill, E., Rushworth, L., Baccarini, M., and Kolch, W. 2004. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306:2267-2270.
229. Piazzolla, D., Meissl, K., Kucerova, L., Rubiolo, C., and Baccarini, M. 2005. Raf-1 sets the threshold of Fas sensitivity by modulating Rok-alpha signaling. J Cell Biol 171:1013-1022.
188
230. Ehrenreiter, K., Piazzolla, D., Velamoor, V., Sobczak, I., Small, J.V., Takeda, J., Leung, T., and Baccarini, M. 2005. Raf-1 regulates Rho signaling and cell migration. J Cell Biol 168:955-964.
231. Storm, S.M., Cleveland, J.L., and Rapp, U.R. 1990. Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene 5:345-351.
232. Barnier, J.V., Papin, C., Eychene, A., Lecoq, O., and Calothy, G. 1995. The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J Biol Chem 270:23381-23389.
233. Luckett, J.C., Huser, M.B., Giagtzoglou, N., Brown, J.E., and Pritchard, C.A. 2000. Expression of the A-raf proto-oncogene in the normal adult and embryonic mouse. Cell Growth Differ 11:163-171.
234. Pritchard, C.A., Bolin, L., Slattery, R., Murray, R., and McMahon, M. 1996. Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr Biol 6:614-617.
235. Wojnowski, L., Zimmer, A.M., Beck, T.W., Hahn, H., Bernal, R., Rapp, U.R., and Zimmer, A. 1997. Endothelial apoptosis in Braf-deficient mice. Nat Genet 16:293-297.
236. Wojnowski, L., Stancato, L.F., Zimmer, A.M., Hahn, H., Beck, T.W., Larner, A.C., Rapp, U.R., and Zimmer, A. 1998. Craf-1 protein kinase is essential for mouse development. Mech Dev 76:141-149.
237. Mikula, M., Schreiber, M., Husak, Z., Kucerova, L., Ruth, J., Wieser, R., Zatloukal, K., Beug, H., Wagner, E.F., and Baccarini, M. 2001. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. Embo J 20:1952-1962.
238. Huser, M., Luckett, J., Chiloeches, A., Mercer, K., Iwobi, M., Giblett, S., Sun, X.M., Brown, J., Marais, R., and Pritchard, C. 2001. MEK kinase activity is not necessary for Raf-1 function. Embo J 20:1940-1951.
239. Avruch, J., Khokhlatchev, A., Kyriakis, J.M., Luo, Z., Tzivion, G., Vavvas, D., and Zhang, X.F. 2001. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56:127-155.
240. Tran, N.H., Wu, X., and Frost, J.A. 2005. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem 280:16244-16253.
241. Brtva, T.R., Drugan, J.K., Ghosh, S., Terrell, R.S., Campbell-Burk, S., Bell, R.M., and Der, C.J. 1995. Two distinct Raf domains mediate interaction with Ras. J Biol Chem 270:9809-9812.
242. Daub, M., Jockel, J., Quack, T., Weber, C.K., Schmitz, F., Rapp, U.R., Wittinghofer, A., and Block, C. 1998. The RafC1 cysteine-rich domain contains multiple distinct regulatory epitopes which control Ras-dependent Raf activation. Mol Cell Biol 18:6698-6710.
189
243. Dhillon, A.S., Meikle, S., Yazici, Z., Eulitz, M., and Kolch, W. 2002. Regulation of Raf-1 activation and signalling by dephosphorylation. Embo J 21:64-71.
244. Chong, H., Lee, J., and Guan, K.L. 2001. Positive and negative regulation of Raf kinase activity and function by phosphorylation. Embo J 20:3716-3727.
245. Mason, C.S., Springer, C.J., Cooper, R.G., Superti-Furga, G., Marshall, C.J., and Marais, R. 1999. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. Embo J 18:2137-2148.
246. Cutler, R.E., Jr., Stephens, R.M., Saracino, M.R., and Morrison, D.K. 1998. Autoregulation of the Raf-1 serine/threonine kinase. Proc Natl Acad Sci U S A 95:9214-9219.
247. Chong, H., and Guan, K.L. 2003. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J Biol Chem 278:36269-36276.
248. Heidecker, G., Huleihel, M., Cleveland, J.L., Kolch, W., Beck, T.W., Lloyd, P., Pawson, T., and Rapp, U.R. 1990. Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol 10:2503-2512.
249. Yip-Schneider, M.T., Miao, W., Lin, A., Barnard, D.S., Tzivion, G., and Marshall, M.S. 2000. Regulation of the Raf-1 kinase domain by phosphorylation and 14-3-3 association. Biochem J 351:151-159.
250. Wellbrock, C., Karasarides, M., and Marais, R. 2004. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875-885.
251. Leicht, D.T., Balan, V., Kaplun, A., Singh-Gupta, V., Kaplun, L., Dobson, M., and Tzivion, G. 2007. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 1773:1196-1212.
252. Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., and Kolch, W. 2011. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2:232-260.
253. Tran, N.H., and Frost, J.A. 2003. Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J Biol Chem 278:11221-11226.
254. Rommel, C., Radziwill, G., Lovric, J., Noeldeke, J., Heinicke, T., Jones, D., Aitken, A., and Moelling, K. 1996. Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Oncogene 12:609-619.
255. Jaumot, M., and Hancock, J.F. 2001. Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions. Oncogene 20:3949-3958.
256. Terai, K., and Matsuda, M. 2005. Ras binding opens c-Raf to expose the docking site for mitogen-activated protein kinase kinase. EMBO Rep 6:251-255.
190
257. Raabe, T., and Rapp, U.R. 2003. Ras signaling: PP2A puts Ksr and Raf in the right place. Curr Biol 13:R635-637.
258. Ory, S., Zhou, M., Conrads, T.P., Veenstra, T.D., and Morrison, D.K. 2003. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol 13:1356-1364.
259. Buday, L., Warne, P.H., and Downward, J. 1995. Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos. Oncogene 11:1327-1331.
260. Roy, S., Lane, A., Yan, J., McPherson, R., and Hancock, J.F. 1997. Activity of plasma membrane-recruited Raf-1 is regulated by Ras via the Raf zinc finger. J Biol Chem 272:20139-20145.
261. Bondeva, T., Balla, A., Varnai, P., and Balla, T. 2002. Structural determinants of Ras-Raf interaction analyzed in live cells. Mol Biol Cell 13:2323-2333.
262. Andresen, B.T., Rizzo, M.A., Shome, K., and Romero, G. 2002. The role of phosphatidic acid in the regulation of the Ras/MEK/Erk signaling cascade. FEBS Lett 531:65-68.
263. Kraft, C.A., Garrido, J.L., Fluharty, E., Leiva-Vega, L., and Romero, G. 2008. Role of phosphatidic acid in the coupling of the ERK cascade. J Biol Chem 283:36636-36645.
264. Williams, J.G., Drugan, J.K., Yi, G.S., Clark, G.J., Der, C.J., and Campbell, S.L. 2000. Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions. J Biol Chem 275:22172-22179.
265. Inder, K., Harding, A., Plowman, S.J., Philips, M.R., Parton, R.G., and Hancock, J.F. 2008. Activation of the MAPK module from different spatial locations generates distinct system outputs. Mol Biol Cell 19:4776-4784.
266. Diaz, B., Barnard, D., Filson, A., MacDonald, S., King, A., and Marshall, M. 1997. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol Cell Biol 17:4509-4516.
267. Xiang, X., Zang, M., Waelde, C.A., Wen, R., and Luo, Z. 2002. Phosphorylation of 338SSYY341 regulates specific interaction between Raf-1 and MEK1. J Biol Chem 277:44996-45003.
268. Edin, M.L., and Juliano, R.L. 2005. Raf-1 serine 338 phosphorylation plays a key role in adhesion-dependent activation of extracellular signal-regulated kinase by epidermal growth factor. Mol Cell Biol 25:4466-4475.
269. King, A.J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., and Marshall, M.S. 1998. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396:180-183.
191
270. Sun, H., King, A.J., Diaz, H.B., and Marshall, M.S. 2000. Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. Curr Biol 10:281-284.
271. Fabian, J.R., Daar, I.O., and Morrison, D.K. 1993. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 13:7170-7179.
272. Marais, R., Light, Y., Paterson, H.F., and Marshall, C.J. 1995. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. Embo J 14:3136-3145.
273. Zang, M., Gong, J., Luo, L., Zhou, J., Xiang, X., Huang, W., Huang, Q., Luo, X., Olbrot, M., Peng, Y., et al. 2008. Characterization of Ser338 phosphorylation for Raf-1 activation. J Biol Chem 283:31429-31437.
274. Ritt, D.A., Zhou, M., Conrads, T.P., Veenstra, T.D., Copeland, T.D., and Morrison, D.K. 2007. CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation. Curr Biol 17:179-184.
275. Zhu, J., Balan, V., Bronisz, A., Balan, K., Sun, H., Leicht, D.T., Luo, Z., Qin, J., Avruch, J., and Tzivion, G. 2005. Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding. Mol Biol Cell 16:4733-4744.
276. Zhang, B.H., and Guan, K.L. 2000. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. Embo J 19:5429-5439.
277. Morrison, D.K., Heidecker, G., Rapp, U.R., and Copeland, T.D. 1993. Identification of the major phosphorylation sites of the Raf-1 kinase. J Biol Chem 268:17309-17316.
278. Zhang, Y., Yao, B., Delikat, S., Bayoumy, S., Lin, X.H., Basu, S., McGinley, M., Chan-Hui, P.Y., Lichenstein, H., and Kolesnick, R. 1997. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 89:63-72.
279. Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marme, D., and Rapp, U.R. 1993. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364:249-252.
280. von Kriegsheim, A., Pitt, A., Grindlay, G.J., Kolch, W., and Dhillon, A.S. 2006. Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5. Nat Cell Biol 8:1011-1016.
281. Park, S., Rath, O., Beach, S., Xiang, X., Kelly, S.M., Luo, Z., Kolch, W., and Yeung, K.C. 2006. Regulation of RKIP binding to the N-region of the Raf-1 kinase. FEBS Lett 580:6405-6412.
282. Rath, O., Park, S., Tang, H.H., Banfield, M.J., Brady, R.L., Lee, Y.C., Dignam, J.D., Sedivy, J.M., Kolch, W., and Yeung, K.C. 2008. The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. Cell Signal 20:935-941.
192
283. Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K.D., Rose, D.W., Mischak, H., et al. 1999. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401:173-177.
284. Yeung, K., Janosch, P., McFerran, B., Rose, D.W., Mischak, H., Sedivy, J.M., and Kolch, W. 2000. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 20:3079-3085.
285. Cirit, M., Wang, C.C., and Haugh, J.M. 2010. Systematic quantification of negative feedback mechanisms in the extracellular signal-regulated kinase (ERK) signaling network. J Biol Chem 285:36736-36744.
286. Balan, V., Leicht, D.T., Zhu, J., Balan, K., Kaplun, A., Singh-Gupta, V., Qin, J., Ruan, H., Comb, M.J., and Tzivion, G. 2006. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell 17:1141-1153.
287. Wu, J., Dent, P., Jelinek, T., Wolfman, A., Weber, M.J., and Sturgill, T.W. 1993. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. Science 262:1065-1069.
288. Hafner, S., Adler, H.S., Mischak, H., Janosch, P., Heidecker, G., Wolfman, A., Pippig, S., Lohse, M., Ueffing, M., and Kolch, W. 1994. Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol 14:6696-6703.
289. Dhillon, A.S., Pollock, C., Steen, H., Shaw, P.E., Mischak, H., and Kolch, W. 2002. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol 22:3237-3246.
290. Dumaz, N., and Marais, R. 2003. Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem 278:29819-29823.
291. Zimmermann, S., and Moelling, K. 1999. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286:1741-1744.
292. Guan, K.L., Figueroa, C., Brtva, T.R., Zhu, T., Taylor, J., Barber, T.D., and Vojtek, A.B. 2000. Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 275:27354-27359.
293. Rommel, C., Clarke, B.A., Zimmermann, S., Nunez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G.D., and Glass, D.J. 1999. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286:1738-1741.
294. Tzivion, G., Luo, Z., and Avruch, J. 1998. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394:88-92.
295. Mischak, H., Seitz, T., Janosch, P., Eulitz, M., Steen, H., Schellerer, M., Philipp, A., and Kolch, W. 1996. Negative regulation of Raf-1 by phosphorylation of serine 621. Mol Cell Biol 16:5409-5418.
193
296. Dhillon, A.S., Yip, Y.Y., Grindlay, G.J., Pakay, J.L., Dangers, M., Hillmann, M., Clark, W., Pitt, A., Mischak, H., and Kolch, W. 2009. The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cell Signal 21:1645-1651.
297. Noble, C., Mercer, K., Hussain, J., Carragher, L., Giblett, S., Hayward, R., Patterson, C., Marais, R., and Pritchard, C.A. 2008. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell 31:862-872.
298. Rushworth, L.K., Hindley, A.D., O'Neill, E., and Kolch, W. 2006. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 26:2262-2272.
299. Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F., and Therrien, M. 2009. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461:542-545.
300. Farrar, M.A., Alberol-Ila, J., and Perlmutter, R.M. 1996. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature 383:178-181.
301. Luo, Z., Tzivion, G., Belshaw, P.J., Vavvas, D., Marshall, M., and Avruch, J. 1996. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383:181-185.
302. Weber, C.K., Slupsky, J.R., Kalmes, H.A., and Rapp, U.R. 2001. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 61:3595-3598.
303. Heidorn, S.J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J.S., Springer, C.J., Pritchard, C., et al. 2010. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221.
304. Matheny, S.A., and White, M.A. 2009. Signaling threshold regulation by the Ras effector IMP. J Biol Chem 284:11007-11011.
305. Chadee, D.N., Xu, D., Hung, G., Andalibi, A., Lim, D.J., Luo, Z., Gutmann, D.H., and Kyriakis, J.M. 2006. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A 103:4463-4468.
306. McKay, M.M., Ritt, D.A., and Morrison, D.K. 2011. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. Curr Biol 21:563-568.
307. Omerovic, J., and Prior, I.A. 2009. Compartmentalized signalling: Ras proteins and signalling nanoclusters. Febs J 276:1817-1825.
308. Kholodenko, B.N., Hancock, J.F., and Kolch, W. 2010. Signalling ballet in space and time. Nat Rev Mol Cell Biol 11:414-426.
309. Kolch, W. 2005. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6:827-837.
194
310. Muller, J., Ory, S., Copeland, T., Piwnica-Worms, H., and Morrison, D.K. 2001. C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol Cell 8:983-993.
311. Therrien, M., Michaud, N.R., Rubin, G.M., and Morrison, D.K. 1996. KSR modulates signal propagation within the MAPK cascade. Genes Dev 10:2684-2695.
312. McKay, M.M., Ritt, D.A., and Morrison, D.K. 2009. Signaling dynamics of the KSR1 scaffold complex. Proc Natl Acad Sci U S A 106:11022-11027.
313. Joneson, T., Fulton, J.A., Volle, D.J., Chaika, O.V., Bar-Sagi, D., and Lewis, R.E. 1998. Kinase suppressor of Ras inhibits the activation of extracellular ligand-regulated (ERK) mitogen-activated protein (MAP) kinase by growth factors, activated Ras, and Ras effectors. J Biol Chem 273:7743-7748.
314. Nguyen, A., Burack, W.R., Stock, J.L., Kortum, R., Chaika, O.V., Afkarian, M., Muller, W.J., Murphy, K.M., Morrison, D.K., Lewis, R.E., et al. 2002. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol Cell Biol 22:3035-3045.
315. Brennan, D.F., Dar, A.C., Hertz, N.T., Chao, W.C., Burlingame, A.L., Shokat, K.M., and Barford, D. 2011. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472:366-369.
316. Hu, J., Yu, H., Kornev, A.P., Zhao, J., Filbert, E.L., Taylor, S.S., and Shaw, A.S. 2011. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc Natl Acad Sci U S A 108:6067-6072.
317. Claperon, A., and Therrien, M. 2007. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene 26:3143-3158.
318. Ziogas, A., Moelling, K., and Radziwill, G. 2005. CNK1 is a scaffold protein that regulates Src-mediated Raf-1 activation. J Biol Chem 280:24205-24211.
319. Rabizadeh, S., Xavier, R.J., Ishiguro, K., Bernabeortiz, J., Lopez-Ilasaca, M., Khokhlatchev, A., Mollahan, P., Pfeifer, G.P., Avruch, J., and Seed, B. 2004. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem 279:29247-29254.
320. Roy, M., Li, Z., and Sacks, D.B. 2004. IQGAP1 binds ERK2 and modulates its activity. J Biol Chem 279:17329-17337.
321. Roy, M., Li, Z., and Sacks, D.B. 2005. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling. Mol Cell Biol 25:7940-7952.
322. Rajalingam, K., and Rudel, T. 2005. Ras-Raf signaling needs prohibitin. Cell Cycle 4:1503-1505.
195
323. Rajalingam, K., Wunder, C., Brinkmann, V., Churin, Y., Hekman, M., Sievers, C., Rapp, U.R., and Rudel, T. 2005. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 7:837-843.
324. Torii, S., Kusakabe, M., Yamamoto, T., Maekawa, M., and Nishida, E. 2004. Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell 7:33-44.
325. DeFea, K.A., Zalevsky, J., Thoma, M.S., Dery, O., Mullins, R.D., and Bunnett, N.W. 2000. beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148:1267-1281.
326. Teis, D., Wunderlich, W., and Huber, L.A. 2002. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev Cell 3:803-814.
327. Teis, D., Taub, N., Kurzbauer, R., Hilber, D., de Araujo, M.E., Erlacher, M., Offterdinger, M., Villunger, A., Geley, S., Bohn, G., et al. 2006. p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J Cell Biol 175:861-868.
328. Sharma, C., Vomastek, T., Tarcsafalvi, A., Catling, A.D., Schaeffer, H.J., Eblen, S.T., and Weber, M.J. 2005. MEK partner 1 (MP1): regulation of oligomerization in MAP kinase signaling. J Cell Biochem 94:708-719.
329. Vomastek, T., Schaeffer, H.J., Tarcsafalvi, A., Smolkin, M.E., Bissonette, E.A., and Weber, M.J. 2004. Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists. Proc Natl Acad Sci U S A 101:6981-6986.
330. Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A.L., Nada, S., and Sabatini, D.M. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141:290-303.
331. Deakin, N.O., and Turner, C.E. 2008. Paxillin comes of age. J Cell Sci 121:2435-2444.
332. Ishibe, S., Joly, D., Zhu, X., and Cantley, L.G. 2003. Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis. Mol Cell 12:1275-1285.
333. Galabova-Kovacs, G., Kolbus, A., Matzen, D., Meissl, K., Piazzolla, D., Rubiolo, C., Steinitz, K., and Baccarini, M. 2006. ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle 5:1514-1518.
334. Wang, H.G., Rapp, U.R., and Reed, J.C. 1996. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87:629-638.
335. Jin, S., Zhuo, Y., Guo, W., and Field, J. 2005. p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem 280:24698-24705.
196
336. Hindley, A., and Kolch, W. 2007. Raf-1 and B-Raf promote protein kinase C theta interaction with BAD. Cell Signal 19:547-555.
337. Le Mellay, V., Troppmair, J., Benz, R., and Rapp, U.R. 2002. Negative regulation of mitochondrial VDAC channels by C-Raf kinase. BMC Cell Biol 3:14.
338. Yamaguchi, O., Watanabe, T., Nishida, K., Kashiwase, K., Higuchi, Y., Takeda, T., Hikoso, S., Hirotani, S., Asahi, M., Taniike, M., et al. 2004. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 114:937-943.
339. Romano, D., Matallanas, D., Weitsman, G., Preisinger, C., Ng, T., and Kolch, W. 2010. Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res 70:1195-1203.
340. Tobiume, K., Matsuzawa, A., Takahashi, T., Nishitoh, H., Morita, K., Takeda, K., Minowa, O., Miyazono, K., Noda, T., and Ichijo, H. 2001. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2:222-228.
341. Matallanas, D., Romano, D., Yee, K., Meissl, K., Kucerova, L., Piazzolla, D., Baccarini, M., Vass, J.K., Kolch, W., and O'Neill, E. 2007. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 27:962-975.
342. O'Neill, E., and Kolch, W. 2005. Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle 4:365-367.
343. Niault, T., Sobczak, I., Meissl, K., Weitsman, G., Piazzolla, D., Maurer, G., Kern, F., Ehrenreiter, K., Hamerl, M., Moarefi, I., et al. 2009. From autoinhibition to inhibition in trans: the Raf-1 regulatory domain inhibits Rok-alpha kinase activity. J Cell Biol 187:335-342.
344. Ehrenreiter, K., Kern, F., Velamoor, V., Meissl, K., Galabova-Kovacs, G., Sibilia, M., and Baccarini, M. 2009. Raf-1 addiction in Ras-induced skin carcinogenesis. Cancer Cell 16:149-160.
345. Zak, R. 1984. Growth of the heart in health and disease: Raven Press, New York.
346. Banerjee, I., Fuseler, J.W., Price, R.L., Borg, T.K., and Baudino, T.A. 2007. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 293:H1883-1891.
347. Gregorio, C.C., and Antin, P.B. 2000. To the heart of myofibril assembly. Trends Cell Biol 10:355-362.
348. Soonpaa, M.H., Kim, K.K., Pajak, L., Franklin, M., and Field, L.J. 1996. Cardiomyocyte DNA synthesis and binucleation during murine development. Am J Physiol 271:H2183-2189.
197
349. Dorn, G.W., 2nd, and Force, T. 2005. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527-537.
350. Heineke, J., and Molkentin, J.D. 2006. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589-600.
351. Fagard, R.H. 1997. Impact of different sports and training on cardiac structure and function. Cardiol Clin 15:397-412.
352. Eghbali, M., Deva, R., Alioua, A., Minosyan, T.Y., Ruan, H., Wang, Y., Toro, L., and Stefani, E. 2005. Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 96:1208-1216.
353. Seidman, J.G., and Seidman, C. 2001. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104:557-567.
354. Sala, V., Gallo, S., Leo, C., Gatti, S., Gelb, B.D., and Crepaldi, T. 2012. Signaling to Cardiac Hypertrophy: Insights from Human and Mouse RASopathies. Mol Med 18:938-947.
355. Drazner, M.H. 2011. The progression of hypertensive heart disease. Circulation 123:327-334.
356. Haider, A.W., Larson, M.G., Benjamin, E.J., and Levy, D. 1998. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32:1454-1459.
357. Berenji, K., Drazner, M.H., Rothermel, B.A., and Hill, J.A. 2005. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 289:H8-H16.
358. Pluim, B.M., Zwinderman, A.H., van der Laarse, A., and van der Wall, E.E. 2000. The athlete's heart. A meta-analysis of cardiac structure and function. Circulation 101:336-344.
359. Grossman, W., Jones, D., and McLaurin, L.P. 1975. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56:56-64.
360. McMullen, J.R., and Jennings, G.L. 2007. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 34:255-262.
361. Kehat, I., and Molkentin, J.D. 2010. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122:2727-2735.
362. Kaplan, M.L., Cheslow, Y., Vikstrom, K., Malhotra, A., Geenen, D.L., Nakouzi, A., Leinwand, L.A., and Buttrick, P.M. 1994. Cardiac adaptations to chronic exercise in mice. Am J Physiol 267:H1167-1173.
198
363. Iemitsu, M., Miyauchi, T., Maeda, S., Sakai, S., Kobayashi, T., Fujii, N., Miyazaki, H., Matsuda, M., and Yamaguchi, I. 2001. Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am J Physiol Regul Integr Comp Physiol 281:R2029-2036.
364. McMullen, J.R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M.C., Kang, P.M., and Izumo, S. 2003. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 100:12355-12360.
365. Rockman, H.A., Ross, R.S., Harris, A.N., Knowlton, K.U., Steinhelper, M.E., Field, L.J., Ross, J., Jr., and Chien, K.R. 1991. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A 88:8277-8281.
366. deAlmeida, A.C., van Oort, R.J., and Wehrens, X.H. 2010. Transverse aortic constriction in mice. J Vis Exp.
367. Lips, D.J., deWindt, L.J., van Kraaij, D.J., and Doevendans, P.A. 2003. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24:883-896.
368. Brower, G.L., Gardner, J.D., Forman, M.F., Murray, D.B., Voloshenyuk, T., Levick, S.P., and Janicki, J.S. 2006. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 30:604-610.
369. McMullen, J.R., Sadoshima, J., and Izumo, S. 2005. Physiological versus pathological cardiac hypertrophy. In Molecular Mechanisms of Cardiac Hypertrophy and Failure. R.A. Walsh, editor. London: Taylor & Francis. 117-136.
370. Evangelista, F.S., Brum, P.C., and Krieger, J.E. 2003. Duration-controlled swimming exercise training induces cardiac hypertrophy in mice. Braz J Med Biol Res 36:1751-1759.
371. Wang, Y., Wisloff, U., and Kemi, O.J. 2010. Animal models in the study of exercise-induced cardiac hypertrophy. Physiol Res 59:633-644.
374. Hina, K., Kusachi, S., Iwasaki, K., Nogami, K., Moritani, H., Kita, T., Taniguchi, G., and Tsuji, T. 1993. Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value. Clin Cardiol 16:403-407.
375. Anan, R., Greve, G., Thierfelder, L., Watkins, H., McKenna, W.J., Solomon, S., Vecchio, C., Shono, H., Nakao, S., Tanaka, H., et al. 1994. Prognostic implications of novel beta
199
cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 93:280-285.
376. Marian, A.J., and Roberts, R. 1995. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 92:1336-1347.
377. Schwartz, K., Carrier, L., Guicheney, P., and Komajda, M. 1995. Molecular basis of familial cardiomyopathies. Circulation 91:532-540.
378. Niimura, H., Bachinski, L.L., Sangwatanaroj, S., Watkins, H., Chudley, A.E., McKenna, W., Kristinsson, A., Roberts, R., Sole, M., Maron, B.J., et al. 1998. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 338:1248-1257.
379. Arad, M., Maron, B.J., Gorham, J.M., Johnson, W.H., Jr., Saul, J.P., Perez-Atayde, A.R., Spirito, P., Wright, G.B., Kanter, R.J., Seidman, C.E., et al. 2005. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 352:362-372.
380. Blair, E., Redwood, C., Ashrafian, H., Oliveira, M., Broxholme, J., Kerr, B., Salmon, A., Ostman-Smith, I., and Watkins, H. 2001. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10:1215-1220.
381. Oliveira, S.M., Ehtisham, J., Redwood, C.S., Ostman-Smith, I., Blair, E.M., and Watkins, H. 2003. Mutation analysis of AMP-activated protein kinase subunits in inherited cardiomyopathies: implications for kinase function and disease pathogenesis. J Mol Cell Cardiol 35:1251-1255.
382. Murphy, R.T., Mogensen, J., McGarry, K., Bahl, A., Evans, A., Osman, E., Syrris, P., Gorman, G., Farrell, M., Holton, J.L., et al. 2005. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 45:922-930.
383. Gripp, K.W., Lin, A.E., Stabley, D.L., Nicholson, L., Scott, C.I., Jr., Doyle, D., Aoki, Y., Matsubara, Y., Zackai, E.H., Lapunzina, P., et al. 2006. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 140:1-7.
384. Porciello, R., Divona, L., Strano, S., Carbone, A., Calvieri, C., and Giustini, S. 2008. Leopard syndrome. Dermatol Online J 14:7.
385. Gripp, K.W., Lin, A.E., Nicholson, L., Allen, W., Cramer, A., Jones, K.L., Kutz, W., Peck, D., Rebolledo, M.A., Wheeler, P.G., et al. 2007. Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. Am J Med Genet A 143A:1472-1480.
386. Rohini, A., Agrawal, N., Koyani, C.N., and Singh, R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61:269-280.
200
387. D'Angelo, D.D., Sakata, Y., Lorenz, J.N., Boivin, G.P., Walsh, R.A., Liggett, S.B., and Dorn, G.W., 2nd. 1997. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 94:8121-8126.
388. Mende, U., Kagen, A., Cohen, A., Aramburu, J., Schoen, F.J., and Neer, E.J. 1998. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A 95:13893-13898.
389. Akhter, S.A., Luttrell, L.M., Rockman, H.A., Iaccarino, G., Lefkowitz, R.J., and Koch, W.J. 1998. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280:574-577.
390. Wettschureck, N., Rutten, H., Zywietz, A., Gehring, D., Wilkie, T.M., Chen, J., Chien, K.R., and Offermanns, S. 2001. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7:1236-1240.
391. Rockman, H.A., Koch, W.J., and Lefkowitz, R.J. 2002. Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212.
392. Wilkins, B.J., and Molkentin, J.D. 2004. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 322:1178-1191.
393. Wilkins, B.J., Dai, Y.S., Bueno, O.F., Parsons, S.A., Xu, J., Plank, D.M., Jones, F., Kimball, T.R., and Molkentin, J.D. 2004. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94:110-118.
395. Clerk, A., and Sugden, P.H. 1999. Activation of protein kinase cascades in the heart by hypertrophic G protein-coupled receptor agonists. Am J Cardiol 83:64H-69H.
396. Conlon, I., and Raff, M. 1999. Size control in animal development. Cell 96:235-244.
397. Neri Serneri, G.G., Boddi, M., Modesti, P.A., Cecioni, I., Coppo, M., Padeletti, L., Michelucci, A., Colella, A., and Galanti, G. 2001. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ Res 89:977-982.
398. Shioi, T., Kang, P.M., Douglas, P.S., Hampe, J., Yballe, C.M., Lawitts, J., Cantley, L.C., and Izumo, S. 2000. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Embo J 19:2537-2548.
399. McMullen, J.R., Shioi, T., Huang, W.Y., Zhang, L., Tarnavski, O., Bisping, E., Schinke, M., Kong, S., Sherwood, M.C., Brown, J., et al. 2004. The insulin-like growth factor 1
201
receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem 279:4782-4793.
400. Luo, J., McMullen, J.R., Sobkiw, C.L., Zhang, L., Dorfman, A.L., Sherwood, M.C., Logsdon, M.N., Horner, J.W., DePinho, R.A., Izumo, S., et al. 2005. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 25:9491-9502.
401. Cantley, L.C. 2002. The phosphoinositide 3-kinase pathway. Science 296:1655-1657.
402. Proud, C.G. 2004. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 63:403-413.
403. Shiojima, I., Sato, K., Izumiya, Y., Schiekofer, S., Ito, M., Liao, R., Colucci, W.S., and Walsh, K. 2005. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115:2108-2118.
404. Marin, T.M., Keith, K., Davies, B., Conner, D.A., Guha, P., Kalaitzidis, D., Wu, X., Lauriol, J., Wang, B., Bauer, M., et al. 2011. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest 121:1026-1043.
405. Rose, B.A., Force, T., and Wang, Y. 2010. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 90:1507-1546.
406. Matsumoto-Ida, M., Takimoto, Y., Aoyama, T., Akao, M., Takeda, T., and Kita, T. 2006. Activation of TGF-beta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 290:H709-715.
407. Fischer, P., and Hilfiker-Kleiner, D. 2008. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol 153 Suppl 1:S414-427.
408. Sugden, P.H., and Clerk, A. 1998. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 83:345-352.
409. Bueno, O.F., and Molkentin, J.D. 2002. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91:776-781.
410. Lorenz, K., Schmitt, J.P., Vidal, M., and Lohse, M.J. 2009. Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol 41:2351-2355.
411. Hunter, J.J., Tanaka, N., Rockman, H.A., Ross, J., Jr., and Chien, K.R. 1995. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 270:23173-23178.
202
412. Zheng, M., Dilly, K., Dos Santos Cruz, J., Li, M., Gu, Y., Ursitti, J.A., Chen, J., Ross, J., Jr., Chien, K.R., Lederer, J.W., et al. 2004. Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol 286:H424-433.
413. Mitchell, S., Ota, A., Foster, W., Zhang, B., Fang, Z., Patel, S., Nelson, S.F., Horvath, S., and Wang, Y. 2006. Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation. Physiol Genomics 25:50-59.
414. Glennon, P.E., Kaddoura, S., Sale, E.M., Sale, G.J., Fuller, S.J., and Sugden, P.H. 1996. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res 78:954-961.
415. Clerk, A., Michael, A., and Sugden, P.H. 1998. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J Cell Biol 142:523-535.
416. Harris, I.S., Zhang, S., Treskov, I., Kovacs, A., Weinheimer, C., and Muslin, A.J. 2004. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110:718-723.
417. Olson, E.N., and Schneider, M.D. 2003. Sizing up the heart: development redux in disease. Genes Dev 17:1937-1956.
418. Bueno, O.F., De Windt, L.J., Tymitz, K.M., Witt, S.A., Kimball, T.R., Klevitsky, R., Hewett, T.E., Jones, S.P., Lefer, D.J., Peng, C.F., et al. 2000. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. Embo J 19:6341-6350.
419. Sanna, B., Bueno, O.F., Dai, Y.S., Wilkins, B.J., and Molkentin, J.D. 2005. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol Cell Biol 25:865-878.
420. Purcell, N.H., Wilkins, B.J., York, A., Saba-El-Leil, M.K., Meloche, S., Robbins, J., and Molkentin, J.D. 2007. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A 104:14074-14079.
421. Kehat, I., Davis, J., Tiburcy, M., Accornero, F., Saba-El-Leil, M.K., Maillet, M., York, A.J., Lorenz, J.N., Zimmermann, W.H., Meloche, S., et al. 2011. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 108:176-183.
422. Nicol, R.L., Frey, N., Pearson, G., Cobb, M., Richardson, J., and Olson, E.N. 2001. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. Embo J 20:2757-2767.
203
423. Kimura, T.E., Jin, J., Zi, M., Prehar, S., Liu, W., Oceandy, D., Abe, J., Neyses, L., Weston, A.H., Cartwright, E.J., et al. 2010. Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res 106:961-970.
424. Liao, P., Georgakopoulos, D., Kovacs, A., Zheng, M., Lerner, D., Pu, H., Saffitz, J., Chien, K., Xiao, R.P., Kass, D.A., et al. 2001. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A 98:12283-12288.
425. Petrich, B.G., Gong, X., Lerner, D.L., Wang, X., Brown, J.H., Saffitz, J.E., and Wang, Y. 2002. c-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. Circ Res 91:640-647.
426. Petrich, B.G., Molkentin, J.D., and Wang, Y. 2003. Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. Faseb J 17:749-751.
427. Knoll, R., Hoshijima, M., Hoffman, H.M., Person, V., Lorenzen-Schmidt, I., Bang, M.L., Hayashi, T., Shiga, N., Yasukawa, H., Schaper, W., et al. 2002. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111:943-955.
428. Brancaccio, M., Fratta, L., Notte, A., Hirsch, E., Poulet, R., Guazzone, S., De Acetis, M., Vecchione, C., Marino, G., Altruda, F., et al. 2003. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med 9:68-75.
429. Heineke, J., Ruetten, H., Willenbockel, C., Gross, S.C., Naguib, M., Schaefer, A., Kempf, T., Hilfiker-Kleiner, D., Caroni, P., Kraft, T., et al. 2005. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci U S A 102:1655-1660.
430. Maron, B.J., Gardin, J.M., Flack, J.M., Gidding, S.S., Kurosaki, T.T., and Bild, D.E. 1995. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785-789.
431. Soor, G.S., Luk, A., Ahn, E., Abraham, J.R., Woo, A., Ralph-Edwards, A., and Butany, J. 2009. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol 62:226-235.
432. Su, I.H., Basavaraj, A., Krutchinsky, A.N., Hobert, O., Ullrich, A., Chait, B.T., and Tarakhovsky, A. 2003. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 4:124-131.
433. Haj, F.G., Markova, B., Klaman, L.D., Bohmer, F.D., and Neel, B.G. 2003. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem 278:739-744.
204
434. Todaro, G.J., and Green, H. 1963. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 17:299-313.
435. Zobel, C., Kassiri, Z., Nguyen, T.T., Meng, Y., and Backx, P.H. 2002. Prevention of hypertrophy by overexpression of Kv4.2 in cultured neonatal cardiomyocytes. Circulation 106:2385-2391.
436. Chan, G., Kalaitzidis, D., Usenko, T., Kutok, J.L., Yang, W., Mohi, M.G., and Neel, B.G. 2009. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood 113:4414-4424.
437. Schoenfeld, J.R., Vasser, M., Jhurani, P., Ng, P., Hunter, J.J., Ross, J., Jr., Chien, K.R., and Lowe, D.G. 1998. Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. J Mol Cell Cardiol 30:2269-2280.
438. Tartaglia, M., and Gelb, B.D. 2005. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 6:45-68.
439. Rauen, K.A., Schoyer, L., McCormick, F., Lin, A.E., Allanson, J.E., Stevenson, D.A., Gripp, K.W., Neri, G., Carey, J.C., Legius, E., et al. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A 152A:4-24.
440. Chan, G., Kalaitzidis, D., and Neel, B.G. 2008. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 27:179-192.
441. Nishikawa, T., Ishiyama, S., Shimojo, T., Takeda, K., Kasajima, T., and Momma, K. 1996. Hypertrophic cardiomyopathy in Noonan syndrome. Acta Paediatr Jpn 38:91-98.
442. Sznajer, Y., Keren, B., Baumann, C., Pereira, S., Alberti, C., Elion, J., Cave, H., and Verloes, A. 2007. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene. Pediatrics 119:e1325-1331.
443. Chen, X., Mitsutake, N., LaPerle, K., Akeno, N., Zanzonico, P., Longo, V.A., Mitsutake, S., Kimura, E.T., Geiger, H., Santos, E., et al. 2009. Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A 106:7979-7984.
444. Marin, T.M., Keith, K., Davies, B., Conner, D.A., Guha, P., Kalaitzidis, D., Wu, X., Bauer, M., Bronson, R., Franchini, K.G., et al. 2010. Rapamycin normalizes hypertrophic cardiomyopathy in a mouse model of LEOPARD Syndrome-associated PTPN11 mutation. J Clin Invest. In revision.
445. Martinelli, S., De Luca, A., Stellacci, E., Rossi, C., Checquolo, S., Lepri, F., Caputo, V., Silvano, M., Buscherini, F., Consoli, F., et al. 2011. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 87:250-257.
205
446. Allanson, J.E., Bohring, A., Dorr, H.G., Dufke, A., Gillessen-Kaesbach, G., Horn, D., Konig, R., Kratz, C.P., Kutsche, K., Pauli, S., et al. The face of Noonan syndrome: Does phenotype predict genotype. Am J Med Genet A 152A:1960-1966.
447. Hasle, H. 2009. Malignant diseases in Noonan syndrome and related disorders. Horm Res 72 Suppl 2:8-14.
448. Maron, B.J., Roberts, W.C., Arad, M., Haas, T.S., Spirito, P., Wright, G.B., Almquist, A.K., Baffa, J.M., Saul, J.P., Ho, C.Y., et al. 2009. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. Jama 301:1253-1259.
449. Ross, J., Jr., and Sobel, B.E. 1972. Regulation of cardiac contraction. Annu Rev Physiol 34:47-90.
450. Nakagawa, O., Ogawa, Y., Itoh, H., Suga, S., Komatsu, Y., Kishimoto, I., Nishino, K., Yoshimasa, T., and Nakao, K. 1995. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 96:1280-1287.
451. Takeda, N., Manabe, I., Uchino, Y., Eguchi, K., Matsumoto, S., Nishimura, S., Shindo, T., Sano, M., Otsu, K., Snider, P., et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 120:254-265.
452. Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:980-984.
453. Barrett, S.D., Bridges, A.J., Dudley, D.T., Saltiel, A.R., Fergus, J.H., Flamme, C.M., Delaney, A.M., Kaufman, M., LePage, S., Leopold, W.R., et al. 2008. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 18:6501-6504.
454. Bertola, D.R., Pereira, A.C., de Oliveira, P.S., Kim, C.A., and Krieger, J.E. 2004. Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation. Am J Med Genet A 130A:378-383.
455. Bueno, O.F., De Windt, L.J., Lim, H.W., Tymitz, K.M., Witt, S.A., Kimball, T.R., and Molkentin, J.D. 2001. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 88:88-96.
456. Xu, J., Ismat, F.A., Wang, T., Lu, M.M., Antonucci, N., and Epstein, J.A. 2009. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 105:304-311.
457. Ieda, M., Tsuchihashi, T., Ivey, K.N., Ross, R.S., Hong, T.T., Shaw, R.M., and Srivastava, D. 2009. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell 16:233-244.
206
458. Miragoli, M., Gaudesius, G., and Rohr, S. 2006. Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circ Res 98:801-810.
459. Margetic, S., Gazzola, C., Pegg, G.G., and Hill, R.A. 2002. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 26:1407-1433.
460. Bjorbaek, C., Buchholz, R.M., Davis, S.M., Bates, S.H., Pierroz, D.D., Gu, H., Neel, B.G., Myers, M.G., Jr., and Flier, J.S. 2001. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 276:4747-4755.
461. Zhang, E.E., Chapeau, E., Hagihara, K., and Feng, G.S. 2004. Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. Proc Natl Acad Sci U S A 101:16064-16069.
462. Opitz, J.M. 1985. The Noonan syndrome. Am J Med Genet 21:515-518.
463. Tartaglia, M., Gelb, B.D., and Zenker, M. 2011. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 25:161-179.
464. Wu, X., Simpson, J., Hong, J.H., Kim, K.H., Thavarajah, N.K., Backx, P.H., Neel, B.G., and Araki, T. 2011. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest 121:1009-1025.
465. Chen, P.C., Wakimoto, H., Conner, D., Araki, T., Yuan, T., Roberts, A., Seidman, C.E., Bronson, R., Neel, B.G., Seidman, J.G., et al. 2010. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J Clin Invest 120:4353-4365.
466. Takeda, N., Manabe, I., Uchino, Y., Eguchi, K., Matsumoto, S., Nishimura, S., Shindo, T., Sano, M., Otsu, K., Snider, P., et al. 2010. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 120:254-265.
467. Dhandapany, P.S., Fabris, F., Tonk, R., Illaste, A., Karakikes, I., Sorourian, M., Sheng, J., Hajjar, R.J., Tartaglia, M., Sobie, E.A., et al. 2011. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. J Mol Cell Cardiol 51:4-15.
468. Johnson, L.N., Lowe, E.D., Noble, M.E., and Owen, D.J. 1998. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett 430:1-11.
469. Chong, H., Vikis, H.G., and Guan, K.L. 2003. Mechanisms of regulating the Raf kinase family. Cell Signal 15:463-469.
470. Karreth, F.A., DeNicola, G.M., Winter, S.P., and Tuveson, D.A. 2009. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell 36:477-486.
207
471. Hinselwood, D.C., Abrahamsen, T.W., and Ekstrom, P.O. 2005. BRAF mutation detection and identification by cycling temperature capillary electrophoresis. Electrophoresis 26:2553-2561.
472. Jung, C.K., Im, S.Y., Kang, Y.J., Lee, H., Jung, E.S., Kang, C.S., Bae, J.S., and Choi, Y.J. 2012. Mutational patterns and novel mutations of BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid.
473. LoRusso, P.M., Krishnamurthi, S.S., Rinehart, J.J., Nabell, L.M., Malburg, L., Chapman, P.B., DePrimo, S.E., Bentivegna, S., Wilner, K.D., Tan, W., et al. 2010. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16:1924-1937.
474. Haura, E.B., Ricart, A.D., Larson, T.G., Stella, P.J., Bazhenova, L., Miller, V.A., Cohen, R.B., Eisenberg, P.D., Selaru, P., Wilner, K.D., et al. 2010. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 16:2450-2457.
475. Morimoto, T., Hasegawa, K., Wada, H., Kakita, T., Kaburagi, S., Yanazume, T., and Sasayama, S. 2001. Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes. J Biol Chem 276:34983-34989.
476. Molkentin, J.D., Lu, J.R., Antos, C.L., Markham, B., Richardson, J., Robbins, J., Grant, S.R., and Olson, E.N. 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-228.
477. Liang, Q., Wiese, R.J., Bueno, O.F., Dai, Y.S., Markham, B.E., and Molkentin, J.D. 2001. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol 21:7460-7469.
478. Camelliti, P., Borg, T.K., and Kohl, P. 2005. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 65:40-51.
479. Gray, M.O., Long, C.S., Kalinyak, J.E., Li, H.T., and Karliner, J.S. 1998. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 40:352-363.
480. Chen, J., Kubalak, S.W., Minamisawa, S., Price, R.L., Becker, K.D., Hickey, R., Ross, J., Jr., and Chien, K.R. 1998. Selective requirement of myosin light chain 2v in embryonic heart function. J Biol Chem 273:1252-1256.
481. Robson, A., Allinson, K.R., Anderson, R.H., Henderson, D.J., and Arthur, H.M. 2010. The TGFbeta type II receptor plays a critical role in the endothelial cells during cardiac development. Dev Dyn 239:2435-2442.
208
482. Lavine, K.J., Long, F., Choi, K., Smith, C., and Ornitz, D.M. 2008. Hedgehog signaling to distinct cell types differentially regulates coronary artery and vein development. Development 135:3161-3171.
483. Sohal, D.S., Nghiem, M., Crackower, M.A., Witt, S.A., Kimball, T.R., Tymitz, K.M., Penninger, J.M., and Molkentin, J.D. 2001. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res 89:20-25.
484. Bhowmick, N.A., Chytil, A., Plieth, D., Gorska, A.E., Dumont, N., Shappell, S., Washington, M.K., Neilson, E.G., and Moses, H.L. 2004. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848-851.
485. Zeisberg, E.M., Tarnavski, O., Zeisberg, M., Dorfman, A.L., McMullen, J.R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W.T., Roberts, A.B., et al. 2007. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13:952-961.
486. Loffredo, F.S., Steinhauser, M.L., Gannon, J., and Lee, R.T. 2011. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 8:389-398.
487. Zheng, B., Zhang, Z., Black, C.M., de Crombrugghe, B., and Denton, C.P. 2002. Ligand-dependent genetic recombination in fibroblasts : a potentially powerful technique for investigating gene function in fibrosis. Am J Pathol 160:1609-1617.
488. Cai, C.L., Martin, J.C., Sun, Y., Cui, L., Wang, L., Ouyang, K., Yang, L., Bu, L., Liang, X., Zhang, X., et al. 2008. A myocardial lineage derives from Tbx18 epicardial cells. Nature 454:104-108.
489. Wu, X., Yin, J., Simpson, J., Kim, K.H., Gu, S., Hong, J.H., Bayliss, P., Backx, P.H., Neel, B.G., and Araki, T. 2012. Increased BRAF Heterodimerization Is the Common Pathogenic Mechanism for Noonan Syndrome-Associated RAF1 Mutants. Mol Cell Biol 32:3872-3890.
490. Moses, K.A., DeMayo, F., Braun, R.M., Reecy, J.L., and Schwartz, R.J. 2001. Embryonic expression of an Nkx2-5/Cre gene using ROSA26 reporter mice. Genesis 31:176-180.
491. Broman, K.W., Wu, H., Sen, S., and Churchill, G.A. 2003. R/qtl: QTL mapping in experimental crosses. Bioinformatics 19:889-890.
492. McClellan, J., and King, M.C. 2010. Genetic heterogeneity in human disease. Cell 141:210-217.
493. Mott, R. 2007. A haplotype map for the laboratory mouse. Nat Genet 39:1054-1056.